115 related articles for article (PubMed ID: 36929154)
1. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed-Release Formulation of Esomeprazole in Healthy Subjects.
Hwang S; Hong SH; Jung J; Chung JY; Jang IJ; Lee S
Clin Pharmacol Drug Dev; 2023 Aug; 12(8):839-844. PubMed ID: 36929154
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.
Kim HC; Yang E; Ban MS; Kim YK; Hong SH; Jung J; Jang IJ; Lee S
Drug Des Devel Ther; 2023; 17():1115-1124. PubMed ID: 37077412
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacodynamics of YYD601, a Dual Delayed-Release Formulation of Esomeprazole, Following Single and Multiple Doses in Healthy Adult Volunteers Under Fasting and Fed Conditions.
Lee HW; Kang WY; Jung W; Gwon MR; Cho K; Yoon YR; Seong SJ
Drug Des Devel Ther; 2022; 16():619-634. PubMed ID: 35281316
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.
Jing S; Zhu Y; Liu W; Yang K; Hu L; Deng D; Lu C; Lin Y
Adv Ther; 2021 Mar; 38(3):1660-1676. PubMed ID: 33575950
[TBL] [Abstract][Full Text] [Related]
5. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
Bae S; Kwon J; Lee SB; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():5099-5108. PubMed ID: 34992346
[TBL] [Abstract][Full Text] [Related]
6. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
8. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
Yi S; Lee H; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS
Aliment Pharmacol Ther; 2017 Aug; 46(3):337-346. PubMed ID: 28543183
[TBL] [Abstract][Full Text] [Related]
9. The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.
Kim D; Park MS; Yoo BW; Hong T; Park SJ; Kim CO
Drug Des Devel Ther; 2019; 13():3151-3159. PubMed ID: 31564831
[TBL] [Abstract][Full Text] [Related]
10. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
11. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
12. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.
Yoon DY; Sunwoo J; Shin N; Kim AR; Kim B; Song GS; Jang IJ; Lee S
Clin Transl Sci; 2021 May; 14(3):934-941. PubMed ID: 33382926
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
15. Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed-Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects.
Kim KN; Yang SW; Kim H; Kwak SS; Kim YS; Cho DY
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):53-58. PubMed ID: 28111929
[TBL] [Abstract][Full Text] [Related]
16. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
[TBL] [Abstract][Full Text] [Related]
18. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
Kukulka M; Eisenberg C; Nudurupati S
Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.
Liu D; Yang H; Jiang J; Nagy P; Shen K; Qian J; Hu P
J Clin Pharmacol; 2016 Jul; 56(7):816-26. PubMed ID: 26970404
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
